ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1559

Vectorcardiography for Identification of Systemic Sclerosis Patients at Risk for Pulmonary Hypertension

S. Ahmed1, Eva Hoekstra2, Katie van der Wouden2, Sum-Che Man2, Kees Swenne2, Madelon Vonk3, Anna-Maria Hoffmann-Vold4, Cosimo Bruni5, Udo Mulder6, Thomas Huizinga7, H.W. Vliegen2 and Jeska de Vries-Bouwstra2, 1Leiden University Medical Centre, Leiden, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 4Oslo University Hospital, Oslo, Norway, 5University of Zurich, Zurich, Switzerland, 6Universitair Medisch Centrum Groningen, Groningen, Netherlands, 7Department of Rheumatology, Leiden University, Leiden, Netherlands

Meeting: ACR Convergence 2024

Keywords: Cohort Study, Heart disease, pulmonary, Scleroderma, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Pulmonary hypertension (PH) in SSc causes significant disease burden and requires invasive diagnosis with right heart catheterization (RHC). Comprehensive work-up is needed to identify patients at risk for PH.(1) Vectorcardiography may represent a novel tool to increase the precision of identification. It can be derived from the 12-lead electrocardiogram (ECG) and has been shown to be a promising tool. (2) In our study, we sought to determine the accuracy of the “ventricular gradient projected on the optimal direction for detection of right ventricular pressure overload” (VG-RVPO) to identify patients with SSc at risk for PH who should be referred for RHC.

Methods: Consecutive SSc patients from the Leiden Combined care in SSc cohort were included. Patients with skin involvement, without known PH, who underwent an RHC in 2021 and 2022 and had an ECG available were included. Data was collected prospectively including history, six-minute walk distance (6MWD), laboratory testing, trans-thoracic echocardiography (TTE), pulmonary function testing and RHC. Standard 10-second 12-lead ECG around the time of the RHC were recorded in the supine position, subsequently collected and processed in Extensible Markup Language (XML) format. A dedicated software program was used to calculate the VG-RVPO, which is defined as the the 3D integral of the heart vector over the QT interval. PH was defined as a mean pulmonary arterial pressure (mPAP) of >20 mmHg. Difference in VG-RVPO between PH status was tested with an unpaired t-test. The association of VG-RVPO with clinical determinants such as 6MWD and diffusing capacity of the lungs for carbon monoxide (DLCO) was assessed with linear regression. Receiver operating characteristic (ROC) analysis was conducted to assess diagnostic accuracy.

Results: The baseline characteristics of the 27 patients that were included, are presented in table 1. The VG-RVPO was higher in patients with PH (-7 millivolt·millisecond [mV·ms]) than in patients without (-19.2 mV·ms) (p=0.02, figure 1A). The VG-RVPO was significantly associated with the 6MWD, DLCO, right ventricular systolic pressure (RVSP) on TTE, NT-proBNP, mPAP and pulmonary vascular resistance (figure 1B and 1C). ROC analysis yielded an area-under-the-curve (AUC) of 0.77, with the optimal cut-off at -16.8 mV·ms. At this cut-off, VG-RVPO held a sensitivity of 93% (95%CI: 70-100) and a specificity of 67% (95%CI: 35-87) (figure 1D).

Conclusion: In this preliminary study, the VG-RVPO is substantially higher in patients with PH and displays promising abilities to identify SSc patients at risk for PH. However, present sample size is too small. Therefore, more cases are being added to determine the independent diagnostic properties of the VG-RVPO to the current standards.

References:

1.            Naranjo M, Hassoun PM. Systemic Sclerosis-Associated Pulmonary Hypertension: Spectrum and Impact. Diagnostics (Basel). 2021;11(5).

2.            Kamphuis VP, Haeck ML, Wagner GS, Maan AC, Maynard C, Delgado V, et al. Electrocardiographic detection of right ventricular pressure overload in patients with suspected pulmonary hypertension. J Electrocardiol. 2014;47(2):175-82.

Supporting image 1

Supporting image 3


Disclosures: S. Ahmed: Janssen, 1, 5; E. Hoekstra: None; K. van der Wouden: None; S. Man: None; K. Swenne: None; M. Vonk: Boehringer-Ingelheim, 2, 6, Janssen, 2, 6, Merck/MSD, 6; A. Hoffmann-Vold: Arxx Therapeutics, 2, Boehringer Ingelheim, 2, 5, 6, 12, Support for travel, Genentech, 2, Janssen, 2, 5, 6, Medscape, 2, 6, 12, Support for travel, Merck/MSD, 2, Novartis, 6, Pliant Therapeutics, 2, Roche, 2, 6, 12, Support for travel, Werfen, 2; C. Bruni: AbbVie/Abbott, 5, Boehringer-Ingelheim, 2, 5, Wellcome Trust, 2; U. Mulder: None; T. Huizinga: Abblynx, 2, 5, 6, Abbott, 2, 5, 6, Boehringer, 2, 5, 6, Bristol Myers Squibb, 2, 5, 6, Eli Lilly, 2, 5, 6, Galapagos, 2, 5, 6, Janssen, 2, 5, 6, Merck, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Roche, 2, 5, 6, Sanofi-Aventis, 2, 5, 6, UCB, 2, 5, 6; H. Vliegen: Boehringer-Ingelheim, 6, Janssen, 1, Novartis, 6; J. de Vries-Bouwstra: AbbVie/Abbott, 2, 6, Boehringer-Ingerlheim, 2, 6, Galapagos, 5, Janssen, 2, 5, 6, Roche, 5.

To cite this abstract in AMA style:

Ahmed S, Hoekstra E, van der Wouden K, Man S, Swenne K, Vonk M, Hoffmann-Vold A, Bruni C, Mulder U, Huizinga T, Vliegen H, de Vries-Bouwstra J. Vectorcardiography for Identification of Systemic Sclerosis Patients at Risk for Pulmonary Hypertension [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/vectorcardiography-for-identification-of-systemic-sclerosis-patients-at-risk-for-pulmonary-hypertension/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/vectorcardiography-for-identification-of-systemic-sclerosis-patients-at-risk-for-pulmonary-hypertension/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology